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Introduction
The dislipidemias are a group of  alterations of  lipoproteínas's 
metabolism that are  correlated with a cardiovascular high risk.
During last the value of  the triglycerides like cardiovascular risk 
factor has put three decades itself  in doubt.[1,2] metodological 
troubles have been one of  the reasons that originated the con-
troversy. The majority of  the epidemiologic studies that the car-
diovascular risk to which the concentrations of  cholesterol are 
correlated and triglycerides have measured have done it assum-
ing that lipids are independent variables among themselves and 
than ailments, in that they raise these parameters, have a similar 
aterogenic. [3] However, these suppositions do not agree with 
recent proofs. [4] the type and lipoproteín's quantity of  various 
classrooms with different capabilities to deposit in ateroma's plate 
reflect The concentration of  these lipids. [5]
The mechanisms for which the hiperlipidemias's bigger cardio-
vascular risk is  explained are multiple. [6,7] a hiperlipidemia's ex-
istence is synonymous of  the  accumulate in one or plus types 
plasma of  lipoproteínas that they have the capacity to deposit in 
ateroma's plates. The majority of  the cases have plasmatic con-
centrations abnormally highs of  remnants of  quilomicrones, of  
lipoproteins of  intermediate or lipoproteins density of  low den-
sity. [8,9] 
The atheroclerotic cardiovascular disease represents the principal 
cause of  the mortality of  the occidental world, implicating high 
costs in the services of  health. 
Although over 200 risk factors for this disease have been identi-
fied, epidemiologic recent studies have proven that you level them 
lifted of  cholesterol, particularly the ones belonging to LDL con-
tinue cholesterol being the risk factor better established for the 
development of  the cardiovascular disease.[10,11]
The success of  any preventive measure depends on in great part 
the knowledge of  the risk factors and of  the impact that its modi-
fication can have on the progression of  the disease. In the case 
of  the cardiovascular disease, we know a good number of  risk 
factors, and fortunately, many are modifiable, for this reason we 
intended to Identify the dislipidemias in patients with izqiemic 
Cardiopathies and to relate with the risk factors cardiovascular 
associates.
Method
A descriptive research came true, taking like universe the older 
individuals of  30 years ( 150 patients ) that they helped to the con-
sultation of  cardiology of  high-technology General Diagnostico's 
Medical Center James Mariño located in the status Aragua at the 
Republic Bolivariana of  Venezuela, in the period from October 
2011 to October  2012. 
The 150 patients that constituted the universe conformed the sign 
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of  our study.
Pregnant women were excluded, patients that suffered intense 
infarct of  the myocardium with less than a month of  convales-
cence, patients with intense infections and those that did not wish 
to take part in investigation. 
The qualitative and quantitative used variables were gathered 
through the case history of  the studied patients and the records 
of  reports of  the clinical laboratory of  the center.
Procedures and collecting techniques
 The physical measurements came true in the consultation of  car-
diology for the doctor and the nurse. The measurements of  labo-
ratory sold off  at Clinical Química's department of  the Clinical 
Laboratory of  the General Santiago Mariño themselves.
The used variables matched:
Sex
Age ( years )
Seric Concentration of  total cholesterol ( mmol L )
Seric concentration  of  HDL ( mmol L )
Seric concentration  of  LDL ( mmol L )
Seric concentration  of  VLDL ( mmol L )
Seric concentration  of  triglycerides ( mmol L )
The determination of  the seric levels of  total cholesterol, HDL 
and triglycerides you accomplished in two occasions each patient, 
signs they were prosecuted in the automated analyst HITACHI 
902, using enzymatic colorimetric methods. 
They were  guided to the patients to spare them fast of  12 hours 
and no taking in alcohol 24 previous hours to the sample take. 
Once the concentration of  total cholesterol was  determined, 
HDL  and triglycerides. Friedewald's formula came from to the 
calculation LDL
LDL c total cholesterol ( triglycerides/2.2 ) - HDL choles-
terol
In the case of  the patients with moral values of  superior triglyc-
erides to 400 mg/dL ( 4,6 mmol L ), Friedewald's formula loses 
validity and the cholesterol served the purpose of  indicator not 
HDL calculated of  the following form:
Cholesterol not total HDL Colesterol - HDL c.
The desirable levels of  cholesterol not HDL is of  30 mg/dL 
more than LDL's level c.
The VLDL obtained itself  by means of  the reason:
VLDL Triglycerides/2.2
Referential interval mg/dL ( mmol L ):
Total cholesterol                              < 200 ( 5,2 )               
                 
HDL c                 > 36 ( 0,9 )
LDL c                 <129 ( 3,4 )  
VLDL 30 ( 0,7 )
Triglycerides                             < 200 ( 2,3 )  
      
Used reproducibility and repetibility like techniques to control 
exactness and precision, in addition to the multi-calibrator them-
selves freeze-dried controls Precinorm Or and Precipath Or with 
standardized concentrations known in normal and pathological 
range.
Pentium created a data base processed in a microcomputer for 
oneself  with the information that was  obtained 4 by means of  
the statistical program SPSS – 10. The descriptive statistical meth-
od of  absolute and relative frequency was applicable. The liked 
Chi's method was  used for the statistical validation. 
Results
Source: Primary record of  data.
Table 1 Characterization of  the patients according to age and sex.
Groups of  ages Sexo Total
Female Male
No. % No % No. %
30 – 40 4 2.7 5 3.3 9 6.0
41 – 50 18 12.0 27 18.0 45 30.0
51 – 60 22 14.7 29 19.3 51 34.0
61 – 70 20 13.3 11 7.3 31 20.6
> of   70 8 5.3 6 4.0 14 9.3
Total 72 48.0 78 52.0 150 100.0
Source: Primary record of  data.
Table 2. Dislipidemias according to the obtained results.
DISLIPIDEMIAS No. %
Yes 95 63.3
No 55 36.7
Total 150 100.0
Source: Primary record of  data p(0.05*)
Table 3: Dislipidemias identified according to results.
DISLIPIDEMIAS No. %
Hypercholesterolemia 36 38.0
Hipertrigliceridemia 19 20.0
Mixed 17 17.8
Hipoalfalipoproteinemia 23 24.2
Total 95 100
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Discussion
The success of  any preventive measure depends on in great part 
the knowledge of  the risk factors and of  the impact that its modi-
fication can have on the progression of  the disease. In the case 
of  the cardiovascular disease, we know a good number of  risk 
factors, and fortunately, many are modifiable, I eat in the case of  
the dislipidemias[12]. 
Source: Primary record of  data.
Table 5. Hypercholesterolemia and your relation with age groups and sex
Groups of  ages HIPERCOLESTEROLEMIA Total
Female Male
No. % No % No. %
30 – 40 1 2.7 3 8.3 4 11.1
41 – 50 5 13.8 11 30.5 16 44.4
51 – 60 6 16.6 7 19.4 13 36.1
61 – 70 3 8.3 - - 3 8.3
> of   70 - - - - - -
Total 15 41.6 21 58.3 36 100.0
Source: Primary record of  data.
Table 6. Hipertrigliceridemia according to age and sex.
Groups of  ages HIPERTRIGLICERIDEMIA Total
Female Male
No. % No % No. %
30 – 40 - - 2 10.5 2 10.5
41 – 50 1 5.3 3 17.8 4 21.0
51 – 60 3 15.8 4 21.0 7 36.8
61 – 70 2 10.5 2 10.5 4 21.0
> of   70 2 10.5 - - 2 10.5
Total 8 42.1 11 57.9 19 100.0
Source: Primary record of  data.
Table 7. Mixed Dislipidemia and your relation with age groups and sex
Groups of  ages DISLIPIDEMIA MIXED Total
Female Male
No. % No % No. %
30 – 40 - - 1 5.88 1 5.88
41 – 50 2 11.76 2 11.76 4 23.52
51 – 60 2 11.76 4 23.52 6 35.29
61 – 70 3 17.64 2 11.76 5 29.4
> of   70 1 5.8 - - 1 5.8
Total 8 47.05 9 52.94 17 100.0
Source: Primary record of  data.
Table 8. Hipoalfalipoproteinemias and your relation with age groups and sex
Groups of  ages HIPOALFALIPOPROTEINEMIAS Total
Female Male
No. % No % No. %
30 – 40 1 4.34 2 8.69 3 13.04
41 – 50 2 8.69 4 17.38 6 26.08
51 – 60 4 17.39 5 21.73 9 39.13
61 – 70 2 8.69 2 8.69 4 17.39
> of   70 1 4.34 - - 1 4.34
Total 10 43.47 13 56.52 23 100.0
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The population's bigger percentage manifested itself  with dislipi-
demias, for a 63.3 %, being the most frequent alteration hyper-
cholesterolemia. The positive and gradual relation of  the concen-
trations of  cholesterol with mortality and morbility for izquemic 
cardiopathy, one observes in men and women, young people and 
old men, in all the races, and so much I eat in patients with clinical 
symptoms of  cardiovascular disease in healthy people [13].
The hypertriglyceridemia, dislipidemia mixed, as well as the 
hipoalfalipoproteinemia it was more frequent in the patients with 
ages understood between 51 and 60 years, representing this pa-
tients' group of  bigger cardiovascular risk, epidemiologic recent 
studies have proven that you level them lifted of  cholesterol, par-
ticularly the ones belonging to LDL continue cholesterol being 
the risk factor better established for the development of  the car-
diovascular disease.
This disease is responsible for 466 over 000 yearly deaths, and 
those people that outlive some intense coronary event, present 
15 times more fatal risk than the remaining population, what de-
pends on also other risk factors and clinical complications [14,15].
Groups patients' poblacionales of  the third age manifested them-
selves without alterations in the levels of  lipids.
The dislipidemias's control is, next to the eradication of  tobacco 
addiction and the control of  the HTA, diabetes, obesity and the 
sedentary life, join of  the principal strategies for the control of  
the cardiovascular diseases. These strategies attempt avoiding the 
implantation of  habits and styles of  life that favor the disease 
( primary prevention ), to avoid the appearing of  new cases of  
disease between free people of  her same ( primary prevention ), 
and enter the ones that right now have suffered a cardiovascular 
previous episode (secondary prevention). [16]
Findings
• Hypercholesterolemia is the most frequent dislipidemia.
• The dislipidemias show up with bigger frequency in the mas-
culine sex and in the ages understood between 41 and 60 
years.
Recommendations
• Developing an intense communal work for the implementa-
tion of  a program of  comprehensive attention of  the dis-
lipidemias
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